TRI SERVICE VACCINE TASK FORCE 7 DEC 90

File: 102596_sep96_decls2_0007.txt
Page: 0007
Total Pages: 8

Subject: TRI SERVICE VACCINE TASK FORCE 7 DEC 90                         

Unit: OTSG        

Parent Organization: HSC         

Box ID: BX003202

Folder Title: DESERT SHIELD MEDICAL ISSUES REVIEW AND AD HOC WORKING GROUP                                    

Document Number:          3

Folder SEQ  #:         31





                                                     UNCLASSIFIED


        SGRD-UWF-J (7 Dec 90)
        SUBJECT:   Vaccines to Prevent Diarrhea and Typhoid Fever in
        operation Desert Shield


        in field trials in Egypt, Chile, and Indonesia. In trials funded
        by the US       in Chile, this vaccine gave 66% protection for at
        least 5 years when 3 enteric coated capsules were given and 4 doses
        was shown to be significantly better than 3 doses, p<0.002. This
        vaccine has now been given to over 100,000 persons without side
        effects. This vaccine will cost the U.S. military $ 2.30 for the
        recommended 4-dose regimen and is available for immediate purchase.
        Although no comparative trials of the killed parenteral and the
        oral vaccines have been done, data is sufficiently strong to
        suggest that the oral vaccine is at least as effective as the
        killed parenteral vaccine.

        RECOMMENDATIONS:

        1. DIARRHEA INITIATIVE. The effective prevention and treatment
        of diarrheal disease is a very high priority during Operation
        Desert Shield.   There are many causes of diarrhea of which ETEC
        and Shiciella are the most prominent causes. Constant surveillance
        of disease rates, etiologies, and antimicrobial susceptibility
        patterns is essential for the most rational way to plan prevention
        sf@A-tegies.

        2.    ETEC/CHOLERA PREVENTION.      The oral cholera vaccine is
        completely safe and has provided significant protection against LT
        ETEC and cholera. This oral cholera vaccine should be purchased
        to vaccinate all U.S. military personnel in the Persian Gulf
        region. This would require 1,000,000 doses (2 doses for 500,000
        personnel). Vaccine ef f icacy field trials should be planned where
        feasible.

        3. ETEC VACCINE. We anticipate that the B subunit/whole cell ETEC
evention
        of ETEC. The oral ETEC vaccine should be developed as rapidly as
        possible. This requires purchase of a test lot from Sweden to test
        for safety and immunogenicity in military personnel stationed in
        the U.S..    Once efficacy has been demonstrated by challenging
        vaccinated volunteers, we will substitute (or add) this vaccine to
        the cholera vaccine.

        4.   ORAL SHIGELLA VACCINES.    Rapid development of an E. coli S.
        sonnei hybrid vaccine entaii-s scheduling of production facilities,
        expedited review of protocols, scheduling of vaccine testing
        centers, and informing the FDA that this project has high priority.
        Following inpatient safety and efficacy studies, large scale
        outpatient safety testing could begin in late March with deployment
        to Desert Shield forces by mid-April.


                                          3

Document 8 f:/Week-36/BX003202/DESERT SHIELD MEDICAL ISSUES REVIEW AND AD HOC WORKING GROUP/tri service vaccine task force 7 dec 90:1018961354253
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003202
Unit = OTSG
Parent Organization = HSC
Folder Title = DESERT SHIELD MEDICAL ISSUES REVIEW AND AD HOC WORKING GROUP
Folder Seq # = 31
Subject = TRI SERVICE VACCINE TASK FORCE 7 DEC 90
Document Seq # = 3
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 18-OCT-1996